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Table 1. Patient characteristics
Characteristic Sternotomy (n=158) VATS (n=33) Thoracotomy (n=10) P-value
Malesex 109(69) 19(57.6) 7(70) 0.433
Age(yr) 57.7±10.6 60±11.7 59.2±8.1 0.497
Smokinghistory 0.551
None 73(46.2) 20(60.6) 5(50)
Ex-smoker 48(30.4) 8(24.2) 4(40)
Currentsmoker 37(23.4) 5(15.2) 1(10)
Symptom 0.188
None 89(56.3) 25(75.8) 5(50)
Chestpain 43(27.2) 3(9.1) 2(20)
Cough 13(8.2) 2(6.1) 1(10)
Face/armswelling 3(1.9) 0 0
Dyspnea 9(5.7) 2(6.1) 2(20)
ECOG 0.283
0 127(80.9) 28(84.8) 7(70)
1 29(18.5) 4(12.1) 3(30)
2 1(0.6) 0 0
3or4 0 1(3) 0
FEV1(%predicted) 0.557
≥80 110(81.5) 21(91.3) 7(77.8)
<80 25(18.5) 2(8.7) 2(22.2)
DLCO(%predicted) 0.847
≥80 62(73.8) 10(71.4) 5(62.5)
<80 22(26.2) 4(28.6) 3(37.5)
BMI(kg/m2) 24±3.1 23.8±1.8 25.2±2.7 0.338
Comorbidity
Diabetes 19(12) 3(9.1) 1(10) 0.911
Hypertension 52(32.9) 9(27.3) 5(5) 0.407
Chronicobstructivepulmonarydisease 6(3.8) 1(3) 0 1.000
Autoimmunedisease 1(0.6) 1(3) 0 0.383
Preoperativebiopsy 66(41.8) 5(15.2) 5(50) 0.012
Neoadjuvanttreatment 35(22.2) 0 3(30) 0.008
Concurrentchemoradiation 5(3.2) 0 0
Chemotherapy 28(17.7) 0 3(30)
Radiotherapy 2(1.3) 0 0
Responseofneoadjuvanttreatment 0.031
Partialresponse 21(77.8) 0 2(66.7)












Table 2. Operative findings, procedures and pathologic findings
Variable Sternotomy (n=158) VATS (n=33) Thoracotomy (n=10) P-value
Extent <0.001
Thymomectomy 17(10.8) 19(57.6) 5(50)
Partialthymectomy 7(4.4) 7(21.2) 1(10)
Totalthymectomy 134(84.8) 7(21.2) 4(40)
Tumorsize 6.4±2.3 4.6±1.8 3.9±2 <0.001
Lymphnodedissection 80(50.6) 8(24.2) 6(60) 0.015
Additionalprocedure 133(84.2) 9(27.3) 9(90) <0.001
Lung,wedgeresection 92(58.2) 5(15.2) 5(50) <0.001
Lung,segmentectomy 2(1.3) 0 1(10) 0.209
Lung,lobectomy 5(3.2) 1(3) 2(20) 0.079
Diaphragm,resection 2(1.3) 0 1(10) 0.209
Pericardium,resection 80(50.6) 4(12.1) 7(70) <0.001
Innominatevein,resection 46(29.1) 0 2(20) <0.001
Phrenicnerve,resection 45(28.5) 2(6.1) 4(40) 0.015
Operationtime(min) 235(115–736) 147(99–196) 356(305–408) <0.001
Bloodloss 350(22–8,000) 135(50–22) 825(450–1,200) <0.001
Transfusion 39(24.8) 0 3(30) 0.005
PathologicTNMstage <0.001
I 57(36.1) 27(81.8) 2(20)
II 10(6.3) 1(3) 1(10)
IIIA 43(27.2) 0 2(20)
IIIB 11(7) 1(3) 0
IVA 20(12.7) 2(6.1) 4(40)
IVB 17(10.8) 2(6.1) 1(10)
Subtype 0.861
Squamouscellcarcinoma 119(78.3) 29(87.9) 9(90)
Lymphoepithelioma-like 6(3.9) 0 0
Sarcomatoid 3(2) 0 0
Mucoepidermoid 2(1.3) 0 0
Adenocarcinoma 3(2) 0 0
Clearcellcarcinoma 1(0.7) 0 0
Nototherwisespecified 11(7.2) 4(12.1) 0
Completeresection 0.216
R0 128(81) 32(97) 7(70)
R1 29(18.4) 0 3(30)
































Table 3. Postoperative outcome
Variable Sternotomy (n=158) VATS (n=33) Thoracotomy (n=10) P-value
Mortalityat30days 2(1.3) 0 0 1.000
Chesttubeduration(day) 5(2–13) 2(1–7) 1.5(0–3) <0.001
Ventilationduration(day) 0(0–6) 0 1(0–2) <0.001
Intensivecareunitstay(day) 1(0–44) 0(0–42) 0.5(0–9) <0.001
Hospitalstay(day) 9(3–63) 4(2–158) 7(4–19) <0.001
Adjuvanttherapy 0.350
None 30(19) 10(30.3) 3(30)
Chemotherapy 35(22.2) 4(12.1) 4(40)
Radiotherapy 73(46.2) 15(45.5) 3(30)
Concurrentchemoradiation 20(12.7) 4(12.1) 0
Complications 44(27.8) 3(9.1) 0 0.014
Prolongedairleak(>5days) 1(0.6) 0 0
Atelectasis 2(1.3) 0 0
Pneumonia 0 0 0
Acutelunginjury 1(0.6) 0 0
Pulmonarythromboembolism 1(0.6) 0 0
Re-intubation 1(0.6) 0 0
Chylothorax 2(1.3) 1(3) 0
Arrhythmia 8(5.1) 0 0
Woundinfection 1(0.6) 0 0
Bleeding 2(1.3) 0 0
Grade 0.134
I 11(7) 2(6.1) 0
II 21(13.3) 0 0
III 10(6.3) 0 0
IV 2(1.3) 1(3) 0




Fig. 1. Overall survival (A) and recurrence-free survival (B) of 201 
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Local 20(33.9) 3(60) 2(40) 0.847
Regional 19(32.2) 1(20) 2(40)
Distant 20(33.9) 1(20) 1(20)




Table 5. Postoperative outcome of patients with tumor less than 5 



















Concomitantprocedure 21(75) 7(25.9) <0.001
Lung,wedgeresection 14(50) 4(14.8) 0.005
Lung,lobectomy 0 1(3.7) 1.000
Pericardium,resection 12(42.9) 3(11.1) 0.008
Innominatevein,resection 8(28.6) 0 0.004
Phrenicnerve,resection 3(10.7) 2(7.4) 1.000
Operationtime(min) 175(115–535) 102(13–215) <0.001
Bloodloss(mL) 375(0–2,000) 5(0–400) <0.001





Mortalityat30days 0 0 1.000
Chesttubeduration(day) 4(2–13) 2(1–7) <0.001
Ventilationduration(day) 0(0–2) 0 0.051
Intensivecareunitstay(day) 1(0–5) 0(0–1) <0.001

















Subgroup analysis for tumor less than 5 cm and clini-


















































Table 5. Continued 
Table 6. Pattern of recurrence of patients with tumor less than 5 














Fig. 2. Overall survival (A) and recurrence-free survival (B) of 
patients with tumor less than 5 cm and tumor-node-metastasis 















































Table 7. Cox regression analysis of prognostic factors of overall survival
Variable
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Sex 0.825 0.472–1.443 0.501
Age 1.006 0.982–1.030 0.626












Chemotherapy 1.300 0.668–2.528 0.440 7.202 1.598–32.455
Radiotherapy 5.987 1.441–24.883 0.014
Concurrentchemoradiation 0.637 0.088–4.620 0.655
Approach 0.089 0.138
Sternotomy Reference Reference Reference Reference
VATS 0.565 0.138–2.317 0.614 0.140–2.689






I Reference Reference Reference Reference
II 0.396 0.052–2.999 0.433 0.051–3.674
III 1.609 0.821–3.155 1.232 0.497–3.053








R0 Reference Reference Reference Reference
R1 1.682 0.941–3.007 1.206 0.652–2.23
Adjuvanttherapy(%)
Chemotherapy 1.211 0.681–2.153 0.514




Table 8. Cox regression analysis of prognostic factors of recurrence-free survival
Variable
Univariate Multivariate
HR 95% CI P-value HR 95% CI P-value
Sex 1.035 0.642–1.669 0.886
Age 0.992 0.972–1.013 0.464
Tumorsize(CT) 1.071 0.964–1.19 0.203
ClinicalTNMstage 0.001 0.020
I Reference Reference Reference Reference
II 5.092 2.234–11.607 3.749 1.418–9.912
III 1.334 0.613–2.905 0.725 0.304–1.728
IV 1.981 1.182–3.32 0.977 0.519–1.839
ClinicalMasaoka-Kogastage <0.001 0.245
I Reference Reference Reference Reference
II 2.066 0.797–5.357 1.452 0.487–4.329
III 3.094 1.469–6.517 1.882 0.679–5.215
IV 6.284 2.96–13.341 2.760 0.992–7.680
Neoadjuvanttreatment
Chemotherapy 2.027 1.218–3.371 0.007 1.106 0.599–2.043 0.748










I Reference Reference Reference Reference
II 1.517 0.507–4.542 1.070 0.304–3.761
III 2.411 1.286–4.518 1.299 0.549–3.075







R0 Reference Reference Reference Reference
R1 1.897 1.1–3.27 0.819 0.438–1.532
Adjuvanttherapy(%) 0.248
Chemotherapy 1.702 1.033–2.804 0.037 1.386 0.796–2.413
Radiotherapy 0.796 0.494–1.285 0.351
HR,hazardratio;CI,confidenceinterval;CT,computedtomography;TNM,tumor-node-metastasis;VATS,video-assistedthoracoscopicsurgery;
NOS,nototherwisespecified.
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0.138),althoughneoadjuvantradiotherapywasassociated
withpoorOS(hazardratio,7.2;95%confidenceinterval,1.6
to32.46;P=0.01).ThemultivariableCoxregressionanalysis
forRFSshowedpathologicTNMstagewasasignificantprog-
nosticfactorofRFS(P=0.045).However,VATShadnoteffect
oneitherORorRFS.
DISCUSSION
Thymiccarcinomasareveryrare,andmostliteraturesabout
thymiccarcinomasareretrospective,small-case,single-cen-
terstudies.Onlyafewretrospectivelarge-samplemulti-
centerstudiesonlong-termoutcomeofthymiccarcinoma
werereportedintheUnitedStates(Surveillance,Epidemiol-
ogy,andEndResultsdatabase,n=290),Europe(European
SocietyofThoracicSurgeonsdatabase,n=229),Japan(Jap-
aneseAssociationforResearchoftheThymusdatabase,
n=306),andChina(ChineseAllianceforResearchofThymo-
madatabase,n=369)[2,11-13].InKorea,theKARTdevel-
opedamulti-institutionalretrospectivedatabasein2014,
andcollectedthedataofthymicepithelialtumor,including
thymiccarcinoma.
Inearlystagethymictumor,surgeryforcompleteresection
hasremainedthemainstayofcurativetreatmentbecause
completeresectionwasasignificantprognosticfactorinthe
manystudiesofthymiccarcinoma[2,14].Traditionally,this
hasbeenconductedwithopenprocedures,especiallymedi-
ansternotomy.AccordingtotheEuropeanSocietyofMedical
Oncology(ESMO)guidelinesonthymictumors,thestandard
surgicalapproachforresectablethymicepithelialtumorre-
mainsmediansternotomy(gradeIV,levelA)[15].Morere-
cently,duetothewidespreaduseofVATS,therehasbeena
progressiveadoptionofthesetechniquesinsurgeryforthy-
miccarcinoma.TheESMOguidelinessuggestthatminimally
invasivesurgeryisanoptionforearlystagetumorinthe
handsofappropriatelytrainedsurgeons.Severaladvantages
ofVATSforthetreatmentofthymictumorshavebeenknown
inanumberofliteraturesinthelastdecade.VATSprovide
noninferioroncologicoutcomesthanopenapproachandis
associatedwithshorterlengthofhospitalstay,reduced
bloodlossanddurationofchesttube[9,14-17].Unfortunate-
ly,mostoftheseliteraturesareretrospectivestudiesandno
randomizedclinicalstudyhasbeenpublishedbecauseofthe
rarityofthymictumor.
Inthepresentstudy,mostpatientswiththymiccarcinoma
whounderwentVATSapproachhadtumorwithlessthan5
cm(meantumorsize,3.8±1.1cm)andTNMstageI(90.9%).
Therefore,weanalyzed55patients(28sternotomyand27
VATS)whohadtumorwithlessthan5cmandclinicalTNM
stageIaccordingtotheapproachofsurgery.VATSwasasso-
ciatedwithshorteroperationtime,lowerbloodloss,reduced
lengthsofPOHS,ICUstay,andchesttubeduration.Further-
more,the5-yearOSandRFSratesandpatternofrecurrence
werenotsignificantlydifferentbetweenthegroups.There-
fore,VATScanbeappliedtopatientswhohadthymiccarci-
nomawithlessthan5cmandclinicalTNMstageI.
VATSwasperformedmostlyinpatientswhodidnotcon-
firmhistologybypreoperativebiopsyaccordingtoourresult.
TheNationalComprehensiveCancerNetworkrecommends
thatsurgicalbiopsyshouldbeavoidedifaresectablethymic
tumorisstronglysuspectedbasedonclinicalandradiologic
features[18].However,histologyofthethymictumorisdiffi-
culttodistinguishbyimagingincaseofsmalltumorwithno
lymphadenopathy[19].Inourseries,althoughthymictumor
revealedtobethymiccarcinoma(WHOtypeC)intraopera-
tivelyorpostoperatively,VATScanbeacceptableifcomplete
resectionwasachieved.
Thepresentstudyhaslimitations.First,thenumberofcas-
esissmallbecauseoftherarityofthymiccarcinoma,with
only201casesover7years.Second,thisisretrospective
study,andselectionbiasexists.Surgeonswouldpreferred
VATSforlessinvasivetumorsuchassmallsizewithoutinva-
siontoinnominateveinorgreatvesselsonpreoperativeCT.
Therefore,weanalyzedsubgroupwhohadtumorwithless
than5cmandTNMstageI.Third,thefollow-upperiodafter
surgeryisslightlyinsufficient.Becausepatientswiththymic
carcinomahavegoodprognosis,afollow-uptimeof10years
ormoremaybenecessarytoidentifysubstantiallong-term
outcomes.Fourth,surgicaltechniques,thedegreeofindivid-
ualskills,andpostoperativecareofindividualcentercould
notbeevaluated.
Inconclusion,theVATSwasappliedfortumorlessthan5
cmandTNMstageI.TheVATSgrouphadshorterdurationof
chesttube,mechanicalventilation,postoperativehospital
day,andlowerincidenceofpostoperativecomplication.The
5-yearOSandRFSwasnotsignificantlydifferentbetween
thegroups.Therefore,theVATSapproachofsurgicaltreat-
mentforthymiccarcinomacanbeselectivelyemployedin
smallandTNMstageItumorwithoutcompromiseofonco-
logicoutcome.
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